CE MARK EXTENSION

The Oraya IRay® Radiotherapy system has received a CE Mark extension for the treatment of choroidal metastases. The new indication of use expands upon Oraya’s prior approval for the treatment of wet age-related macular degeneration (AMD).
“This oncology indication demonstrates the breadth of possibilities that are enabled by the proprietary aspects of the IRay platform,” Oraya CEO Jim Taylor said. “While Oraya’s primary focus remains on treating wet AMD, we continue to identify and evaluate other uses of the technology that may benefit patients and clinicians,” he said.
www.orayainc.com